Victory Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.56M | Sell |
219,254
-15,836
| -7% | -$374K | ﹤0.01% | 1334 |
|
|
2026
Q1 | $5.31M | Sell |
235,090
-107,223
| -31% | -$2.38M | ﹤0.01% | 1302 |
|
|
2025
Q4 | $8.86M | Buy |
342,313
+55,945
| +20% | +$1.33M | 0.01% | 1093 |
|
|
2025
Q3 | $7.38M | Buy |
286,368
+64,524
| +29% | +$1.58M | ﹤0.01% | 1209 |
|
|
2025
Q2 | $5.3M | Buy |
221,844
+14,289
| +7% | +$360K | ﹤0.01% | 1301 |
|
|
2025
Q1 | $5.16M | Buy |
207,555
+112,805
| +119% | +$2.7M | 0.01% | 1269 |
|
|
2024
Q4 | $1.79M | Sell |
94,750
-27,478
| -22% | -$482K | ﹤0.01% | 1539 |
|
|
2024
Q3 | $1.84M | Buy |
122,228
+34,589
| +39% | +$591K | ﹤0.01% | 1506 |
|
|
2024
Q2 | $2.51M | Buy |
87,639
+13,776
| +19% | +$392K | ﹤0.01% | 1373 |
|
|
2024
Q1 | $2.16M | Buy |
73,863
+8,299
| +13% | +$255K | ﹤0.01% | 1431 |
|
|
2023
Q4 | $2.21M | Sell |
65,564
-3,123
| -5% | -$91.4K | ﹤0.01% | 1400 |
|
|
2023
Q3 | $2.11M | Sell |
68,687
-1,446
| -2% | -$52.1K | ﹤0.01% | 1379 |
|
|
2023
Q2 | $2.81M | Buy |
70,133
+2,367
| +3% | +$97.9K | ﹤0.01% | 1312 |
|
|
2023
Q1 | $2.77M | Buy |
67,766
+3,189
| +5% | +$127K | ﹤0.01% | 1329 |
|
|
2022
Q4 | $2.49M | Sell |
64,577
-9,446
| -13% | -$460K | ﹤0.01% | 1366 |
|
|
2022
Q3 | $3.94M | Buy |
74,023
+8,785
| +13% | +$489K | ﹤0.01% | 1299 |
|
|
2022
Q2 | $3.8M | Sell |
65,238
-6,079
| -9% | -$398K | ﹤0.01% | 1304 |
|
|
2022
Q1 | $5.4M | Sell |
71,317
-3,356
| -4% | -$224K | 0.01% | 1281 |
|
|
2021
Q4 | $4.49M | Buy |
74,673
+2,899
| +4% | +$160K | ﹤0.01% | 1351 |
|
|
2021
Q3 | $4.02M | Buy |
71,774
+2,908
| +4% | +$168K | ﹤0.01% | 1386 |
|
|
2021
Q2 | $4.18M | Sell |
68,866
-15,193
| -18% | -$962K | ﹤0.01% | 1405 |
|
|
2021
Q1 | $5.89M | Buy |
84,059
+67,140
| +397% | +$4.8M | 0.01% | 1282 |
|
|
2020
Q4 | $1.01M | Sell |
16,919
-893
| -5% | -$52.3K | ﹤0.01% | 1781 |
|
|
2020
Q3 | $1.07M | Buy |
17,812
+5,089
| +40% | +$296K | ﹤0.01% | 1667 |
|
|
2020
Q2 | $668K | Buy |
12,723
+814
| +7% | +$34K | ﹤0.01% | 1888 |
|
|
2020
Q1 | $399K | Buy |
11,909
+90
| +0.8% | +$3.74K | ﹤0.01% | 1922 |
|
|
2019
Q4 | $535K | Buy |
11,819
+2,974
| +34% | +$126K | ﹤0.01% | 1980 |
|
|
2019
Q3 | $337K | Buy |
+8,845
| New | +$353K | ﹤0.01% | 2033 |
|
|
2016
Q3 | – | Sell |
-525
| Closed | -$18K | – | 1822 |
|
|
2016
Q2 | $18K | Buy |
525
+22
| +4% | +$1.08K | ﹤0.01% | 1600 |
|
|
2016
Q1 | $27K | Buy |
503
+37
| +8% | +$2.16K | ﹤0.01% | 1586 |
|
|
2015
Q4 | $36K | Buy |
466
+273
| +141% | +$15.5K | ﹤0.01% | 1609 |
|
|
2015
Q3 | $8K | Buy |
193
+18
| +10% | +$1.1K | ﹤0.01% | 1609 |
|
|
2015
Q2 | $12K | Buy |
+175
| New | +$13.8K | ﹤0.01% | 1616 |
|
Other funds holding PCRX
DPCM
Victory Capital Management's PCRX Position: Q2 2026 in Review
Victory Capital Management reduced its Pacira BioSciences (PCRX) stake by 6.7% in Q2 2026, selling an estimated $374K and leaving 219,254 shares worth $5.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1334.
Victory Capital Management first reported a position in PCRX in Q2 2015 and has held it in 33 quarters since. The position peaked at $8.86M in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Victory Capital Management held 219,254 shares of Pacira BioSciences worth $5.56M as of Q2 2026.
- Victory Capital Management sold 15,836 Pacira BioSciences shares in Q2 2026, an estimated $374K.
- Pacira BioSciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1334 holding.
- Victory Capital Management first reported a position in Pacira BioSciences in Q2 2015 and has held it in 33 quarters since.
- Victory Capital Management's Pacira BioSciences position peaked at $8.86M in Q4 2025.
- 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.